Our Leadership Team

Courtney Rutkowski, Founder and Chief Engagement Officer

With over 25 years of experience in healthcare and life sciences, Courtney excels in building commercial frameworks that attract top talent, foster innovation, and drive collaborative problem-solving.

Her strategic approach has consistently exceeded revenue expectations in over 10 novel therapeutic product launches, achieving accelerated timelines across multiple rare disease areas. She has successfully built multiple first-in-class sales organizations aligned with startup goals, driving rapid market traction and revenue growth. Leveraging her market expertise, Courtney consistently creates demand through targeted campaigns, ensuring swift market penetration.

By optimizing talent acquisition and leveraging a deep understanding of the market ecosystem, Courtney has demonstrated a strong aptitude for establishing high-performing teams that deliver immediate and sustained impact. Her skill in fostering cross-functional collaboration, aligning resources, and forming strategic partnerships maximizes revenue and ensures successful product launches, whether within minimal or extended timelines.

Stephanie Collins, RN, BSN, BCPA, Founder and Chief Patient Officer

Stephanie is a visionary leader with over 30 years of experience in healthcare and life sciences, specializing in the commercialization of first-in-class therapies for specialty and rare diseases. As Chief Patient Advocacy Officer at Eido Bio, she brings her expertise in successfully launching 15 products, including groundbreaking advancements in women's health, to drive patient-centric strategies and ensure transformative therapies reach those who need them most. 

With a unique background in nursing and patient advocacy, Stephanie's career has been defined by her unwavering commitment to improving patient outcomes. She has consistently championed disease awareness campaigns and worked tirelessly to ensure that patients with rare and chronic conditions are seen, heard, and provided access to innovative treatments. Her leadership was instrumental in spearheading 15 successful product launches, including the first diagnostic and treatment paradigm shift for a common chronic disease in over a century. 

Stephanie's experience spans roles at leading companies such as Intermune, UCB, Vertex, BMS, Intercept, Insmed, and Provention Bio, where she has been pivotal in building and preparing markets for first-in-class therapies. Her active involvement with key industry organizations allows her to drive public policy and access initiatives, contributing to meaningful improvements in care quality and accessibility. Stephanie's multidisciplinary background in nursing, biology, and business, combined with her passion for bridging the gap between unmet needs and treatment, brings a unique, holistic perspective to Eido Bio's strategic initiatives, advancing the company's mission to deliver innovative therapies that address critical unmet needs and fill significant treatment gaps in patient care. 

''

Traci Carman, CPA, Founder and Chief Executive Officer

Traci Carman, CPA, is the Co-Founder and Chief Executive Officer of Eido Bio. Ms. Carman has dedicated her career to developing innovative therapies for patients whose urgent medical needs are currently unmet by the current therapeutic landscape. She is an experienced finance executive with more than 20 years of experience leading startups and public companies, and deep expertise in IP strategy and regulatory execution to accelerate approvals.

Prior to co-founding Eido, Ms. Carman was a co-founder and Chief Financial Officer at Receptor Life Sciences, Inc., a company developing inhaled therapeutic products for conditions including chronic pain, neurologic diseases, and inflammatory disorders, which was successfully licensed to MannKind in 2024.

She has served on the Board of Directors for various companies, including Swedish Medical Foundation (present), Technology Access Foundation, Receptor Life Sciences, and Eido Bio (present). Ms. Carman began her career in finance at DISCOVERMUSIC.COM Inc., where she orchestrated a successful acquisition and exit by Loudey Technologies. She earned her B.A. in Business Administration and Finance at Washington State University and is a Certified Public Accountant and member of the Washington State Board of Accountancy.

Greg Schiffman, MBA, Board Member

Gregory Schiffman is an accomplished senior finance executive with more than 25 years of strategic and operational finance, treasury, corporate development, manufacturing and logistics experience.  Mr. Schiffman has been a CFO and an Independent Director of both public and private companies for over 20 years.

He was the CFO of ABSCI, taking them public through an IPO process in 2021, was the CFO at Vineti, Lion Biotechnologies, Inc., which has since been renamed Iovance Biotherapeutics, Inc., and served as Executive Vice President and CFO at StemCells, Inc., Dendreon Corp. and Affymetrix.  Prior to these roles, Mr. Schiffman was Vice President and Controller at Applied BioSystems where he managed global financial operations and at Hewlett Packard he headed up a variety of global assignments including international finance assignments in Europe and Asia, and was a VP of Manufacturing for a U.S. manufacturing operation. 

Mr. Schiffman received an M.B.A. from Northwestern University’s Kellogg School of Management, is a CPA and holds a bachelor’s degree in accounting from De Paul University.